Skip directly to content

About SOMAVERT

If you still have high levels of IGF-I and are experiencing signs and symptoms of acromegaly after surgery or radiation, SOMAVERT may be a treatment option

SOMAVERT was studied in a clinical trial for 12 weeks in 112 patients. Patients were given either a daily 10-mg dose, a 15-mg dose, a 20-mg dose or a placebo dose.

SOMAVERT can help patients
with acromegaly lower IGF-I levels

For all 3 doses in the clinical trial, SOMAVERT significantly lowered insulin-like growth factor I (IGF-I) levels at 12 weeks*

Within 2 weeks, SOMAVERT rapidly reduced IGF-I levels and worked for a majority of patients to achieve normal IGF-I levels at 12 weeks

In an open-label extension of the study, 93% of patients had normal IGF-I levels during at least 1 doctor visit, while taking SOMAVERT for an average of 43 weeks

SOMAVERT works to reduce signs
and symptoms of acromegaly

SOMAVERT improved ring size and total score of signs and symptoms of acromegaly (swelling, joint pain, headache, sweating, and weakness) compared to placebo in the 12-week trial

In a review of the clinical study, 91% of patients (52 out of 57 patients) who reached a normal IGF-I level also
reported improvement in at least one sign or symptom of acromegaly within the 12-month
follow-up period to the 12-week clinical trial

*These data are from a clinical trial that involved 112 patients with acromegaly. Thirty-two patients received a placebo. Eighty were treated with SOMAVERT at 1 of 3 dosage strengths. The primary efficacy endpoint was IGF-I percent change in IGF-I concentrations from baseline to week 12. The average percent change from baseline in IGF-I was -27 at 10 mg/day, -48 at 15 mg/day, and -63 at 20 mg/day. Results of the secondary endpoint for patients achieving normal IGF-I levels for their age were 10% of patients taking a placebo, 39% of those on 10 mg of SOMAVERT per day, 75% of those on 15 mg of SOMAVERT per day, and 82% of those on 20 mg of SOMAVERT per day.

These data come from the extension to the original clinical study of 109 patients (including 6 new patients).

In a review of the clinical study, of the 57 patients who reached a normal IGF-I level and had at least 1 sign or symptom of acromegaly (fatigue, excessive perspiration, headache, arthralgia, and soft-tissue swelling) at the time of normalization, 91% (52 out of 57 patients) reported improvement in these signs and symptoms at the time of normalization or thereafter.